|
|
|
|
|
|
by frodo8sam
725 days ago
|
|
|
The problem is also that this class of drugs (modified peptides) is produced in a very different way from most drugs (small molecules). When small molecule GLP-1 receptor agonists hit the market the shortage will be over very quickly. There is a lot of capacity to produce small molecules in place already. Many companies are currently racing to bring small molecules to market. |
|
|